Combining nice dividends with a growing industry that comprises roughly one-fifth of the nation's GDP should make for an attractive stock -- in theory. Unfortunately, the theoretical doesn't always translate...... (read more)

What's the source of your investment strategy? Many look to great investors like Warren Buffett for guidance on how to invest. Some take what we at the Fool call a "motley approach" and try a little bit...... (read more)

Janus Fund (JANDX) bares the name of the fund family behind it. The flagship offering focuses on growth. Three healthcare stocks that underperformed for the fund in 2012 still appear to have growth potential...... (read more)

The trick to buying dividend stocks isn't to look for the ones with the highest yield. Dividends aren't guaranteed, and when dividends are really high, there's often a reason investors are demanding a...... (read more)

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have appreciated significantly in 2013 so far, and it seems that the trend might continue for the rest of the year. Vertex is a biotech company...... (read more)

Biotechs with market caps of a billion dollars or more are a dime a dozen. Well, actually, they're more like $12 billion or more a dozen, but you get the point. There are plenty of them. However, most...... (read more)

They're demanding. They take risks -- but only calculated ones. And they ask lots of penetrating questions to understand as much as possible before putting a dime on the line. Venture capitalists, or...... (read more)

As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector. A PDUFA decision, as well as three FDA panel reviews/findings provided the impetus for some big moves; however...... (read more)

There are many biotech stocks to choose from that have long-lasting value. Each one can potentially have huge value, but there is a group of biotech stocks that focus only on orphan drugs. You might ask...... (read more)